Brought to you by 
Annapurna licenses three Weill Cornell gene therapy programs
25 Apr 2016
Executive Summary
Annapurna Therapeutics SAS (formerly AAVLife) licensed three gene therapy programs developed in the lab of Weill Cornell Medical College's Ronald Crystal, MD, who's also a co-founder and chief scientific advisor at Annapurna.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Annapurna licenses three Weill Cornell gene therapy programs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice